Migraine Treatment Availability in Hospital Pharmacies

This covers which drug classes migraine treatment in India actually spans, why migraine-specific drugs remain underused, what's in the National List of Essential Medicines, and why migraine treatment availability hospital pharmacy stocking often reflects prescribing habit more than treatment guidance.

Which drug classes treat migraine in India?

Acute migraine treatment spans NSAIDs, paracetamol-based fixed-dose combinations, ergot derivatives, and triptans such as sumatriptan and rizatriptan, while preventive treatment relies on tricyclic antidepressants, beta-blockers like propranolol, and flunarizine. Newer calcitonin gene-related peptide-targeted therapies, delivered as monoclonal antibodies or oral gepants, have also entered clinical use, with a gepant tablet formulation now approved by India's drug regulator for acute treatment in patients with an inadequate response to triptans.

Naproxen combined with domperidone and paracetamol was the most commonly used abortive regimen in published Indian prescribing data, well ahead of migraine-specific agents. This reflects a genuine prescribing pattern, not a data artefact, and it is the pattern a hospital's own reorder logic should be built against rather than against an idealised drug list.

Why are migraine-specific drugs like triptans so rarely prescribed?

Underuse traces partly to a documented information gap rather than drug unavailability alone. A peer-reviewed evaluation of Indian drug information sources for ergot derivatives and triptans found major deficiencies: government references like the CDSCO website scored under 22% complete against seven core prescribing parameters including contraindications, adverse reactions and pregnancy category, while a leading commercial compendium scored above 97%.

Since migraine disproportionately affects women of reproductive age, the near-total absence of pregnancy-category information across most Indian sources is a specific and consequential gap, one the study's authors flagged as requiring urgent correction. A prescriber who cannot quickly verify a triptan's pregnancy safety profile from an authoritative government source has a real, structural reason to default to a familiar NSAID combination instead.

What does the National List of Essential Medicines cover for migraine?

Propranolol and sumatriptan both appear in India's National List of Essential Medicines 2022, the 384-drug list that determines what public health programmes prioritise for procurement and access. Amitriptyline is also listed, though under psychiatric and palliative-care indications rather than a dedicated migraine category, reflecting its use as an off-label preventive agent rather than a purpose-built one.

Ergot derivatives and most other triptans beyond sumatriptan sit outside the essential list entirely, which means their availability through public-sector supply chains depends on individual state procurement decisions rather than a mandated national baseline. A hospital in a state that hasn't separately budgeted for these agents may simply never see them move through public-sector channels.

This matters more in a tertiary referral centre than in a small clinic, since a hospital running a dedicated headache or neurology outpatient service sees genuine demand for the non-essential-list triptans that a general facility rarely encounters. Procurement teams working purely off the essential-medicines list can miss that demand entirely.

How does this affect what a hospital pharmacy should actually stock?

A pharmacy stocking migraine treatment purely against national essential-medicines status will carry propranolol and sumatriptan but may miss the ergot derivatives, additional triptans and newer gepant-class drugs a specialist neurology outpatient service increasingly prescribes. Matching stock to the hospital's own department mix, rather than to the essential list alone, closes that gap.

A tertiary centre running an active headache clinic sees a materially different migraine prescribing pattern than a general hospital where migraine is one presentation among many seen in the emergency department. The reorder point for triptans and gepants should track that department-level volume, not a system-wide average that dilutes a specialist unit's actual demand.

Emergency departments also need their own migraine formulary logic, separate from the outpatient neurology clinic's. Acute severe migraine presenting at night often gets treated with parenteral options the outpatient clinic never touches, and a pharmacy that only stocks oral triptans for daytime prescribing leaves the emergency department short exactly when a patient is in the most pain.

What happens when a prescribed migraine drug isn't in stock?

When a neurologist writes a triptan or a newer CGRP-targeted agent the hospital's own pharmacy doesn't carry, the patient has to source it from an outside chemist. That chemist is often less familiar with a drug class that remains genuinely under-prescribed and under-stocked across India.

That trip outside the hospital is also the exact moment the hospital loses both the sale and the ability to verify the patient actually filled and is taking the prescribed treatment.

Our managed hospital pharmacy services guide covers how reliable in-house stocking for lower-volume specialist drug classes like migraine-specific agents keeps a neurology department's prescriptions from leaking to outside pharmacies, and our prescription leakage piece covers the broader revenue and continuity-of-care cost of that pattern across a hospital's specialties.

Sources

1. 1Information on migraine drugs in commonly available Indian drug information sources – Whether we satisfied the community needs? — National Institutes of Health, National Library of Medicine
2. 2National List of Essential Medicines 2022 — Central Drugs Standard Control Organisation
3. 3The acute and preventative treatment of episodic migraine — National Institutes of Health, National Library of Medicine
4. 4Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale — National Institutes of Health, National Library of Medicine
5. 5List of New Drugs approved in the year 2025 — Central Drugs Standard Control Organisation

This article is for informational purposes and is not a substitute for professional medical advice. Migraine drug selection is a clinical decision made by the treating physician based on individual patient history and response; this article does not recommend a specific treatment for any individual case.